Theranos

Scope

Theranos, Inc.'s blood-testing business and technology claims, especially the 2013–2016 retail-testing period; regulatory findings concerning its clinical laboratory; civil securities enforcement; federal criminal prosecutions of Elizabeth Holmes and Ramesh "Sunny" Balwani; the different verdicts returned by separate juries; sentencing/restitution; and appellate review.

This dossier is not a biography of Elizabeth Holmes, a complete corporate history of Theranos, or a general page about medical-device regulation.

Key distinctions

• "Theranos test" is not one technological object. Patient samples were processed on Theranos-developed Edison devices, modified third-party commercial analyzers, and unmodified third-party analyzers. The miniLab was a separate development-stage system.
• "Fingerstick testing" does not imply "tested on a Theranos proprietary analyzer." A fingerstick sample could be collected in a Theranos nanotainer and then run on an Edison or modified third-party machine.
• A published testing menu is not a device-capability list. Theranos advertised/offered a broad test menu, while the Ninth Circuit record says only twelve assays were ever run on the Edison.
• FDA clearance of one assay is not FDA validation of the whole platform. FDA's K143236 record shows a Theranos HSV-1 IgG assay received a 510(k) substantially-equivalent decision; it does not establish that the Edison could accurately perform the entire advertised menu.
• SEC complaint ≠ SEC adjudicated merits finding. Holmes and Theranos settled SEC charges without admitting or denying the allegations.
• Criminal indictment ≠ conviction.
• Holmes verdict ≠ Balwani verdict. The two defendants were tried separately and juries reached materially different patient-fraud outcomes.
• Acquittal ≠ affirmative factual finding that patient tests were accurate or that no patient was harmed.
• CMS regulatory "immediate jeopardy" finding ≠ criminal fraud verdict.
• Sentencing narrative / government characterization of trial evidence ≠ jury finding on every described event.
• Court-hosted trial exhibit ≠ judicial finding. A Theranos document remains a Theranos-authored document even when preserved on cand.uscourts.gov.

Questions and claims

• C-1 — "Theranos was charged" vs "Theranos/Holmes admitted fraud"(question / dispute)
• C-2 — Holmes verdict vs Balwani verdict(question / dispute)
• C-3 — Patient-test problems vs Holmes's patient-count acquittals(question / dispute)
• C-4 — "Theranos testing" denominator problem(question / dispute)
• C-5 — "The technology was fake" vs specific FDA clearance(question / dispute)
• C-6 — CMS regulatory finding vs fraud finding(question / dispute)
• C-7 — Trial exhibit vs judicial finding(question / dispute)
• C-8 — Appellate opinion source-version drift(question / dispute)
• C-9 — "Affirmed" vs "final beyond further review"(question / dispute)

Analysis

Theranos is a near-perfect test of adjudicative posture discipline.

A conventional summary easily compresses all of the following into "Theranos was fraud":

Counterpedia should make those objects visually and graphically impossible to confuse.

• a company claim;
• an internal or first-party document;
• an SEC allegation;
• an SEC settlement without admission;
• a CMS regulatory deficiency finding;
• a criminal indictment;
• trial evidence;
• a guilty verdict;
• an acquittal;
• a dismissed count;
• a hung count;
• a sentence;

Temporal bounds

Primary demo period: 2010–2026, with emphasis on:

• 2013–2015 retail testing / fundraising;
• 2015–2016 CMS/FDA regulatory period;
• 2018 SEC and criminal charging;
• 2021–2022 trials and verdicts;
• 2022 sentencing;
• 2025 Ninth Circuit opinion and amended opinion;
• 2026 pending Supreme Court petition by Balwani.